CA2797098C - Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof - Google Patents

Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof Download PDF

Info

Publication number
CA2797098C
CA2797098C CA2797098A CA2797098A CA2797098C CA 2797098 C CA2797098 C CA 2797098C CA 2797098 A CA2797098 A CA 2797098A CA 2797098 A CA2797098 A CA 2797098A CA 2797098 C CA2797098 C CA 2797098C
Authority
CA
Canada
Prior art keywords
dosage form
active agent
biologically active
form according
liquid biologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2797098A
Other languages
English (en)
French (fr)
Other versions
CA2797098A1 (en
Inventor
Francois Ravenelle
Dorothee Le Garrec
David Lessard
Sandra Gori
Damon Smith
Miloud Rahmouni
Vinayak Sant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paladin Labs Inc
Endo Ventures Ltd
Original Assignee
Paladin Labs Barbados Inc
Paladin Labs Inc
Paladin Labs Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paladin Labs Barbados Inc, Paladin Labs Inc, Paladin Labs Europe Ltd filed Critical Paladin Labs Barbados Inc
Publication of CA2797098A1 publication Critical patent/CA2797098A1/en
Application granted granted Critical
Publication of CA2797098C publication Critical patent/CA2797098C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2797098A 2010-04-23 2011-04-21 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof Active CA2797098C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32734810P 2010-04-23 2010-04-23
US61/327,348 2010-04-23
PCT/CA2011/000447 WO2011130834A1 (en) 2010-04-23 2011-04-21 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof

Publications (2)

Publication Number Publication Date
CA2797098A1 CA2797098A1 (en) 2011-10-27
CA2797098C true CA2797098C (en) 2019-03-26

Family

ID=44833585

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2797098A Active CA2797098C (en) 2010-04-23 2011-04-21 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof

Country Status (6)

Country Link
US (1) US20130039864A1 (enExample)
EP (1) EP2563349A4 (enExample)
JP (2) JP2013530931A (enExample)
CA (1) CA2797098C (enExample)
IL (1) IL222568A (enExample)
WO (1) WO2011130834A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
CA2797098C (en) * 2010-04-23 2019-03-26 Labopharm Inc. Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
US11331271B2 (en) * 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
JP6912876B2 (ja) * 2016-10-06 2021-08-04 三洋化成工業株式会社 アクリル系医薬固形製剤用添加剤
GB2561009B (en) * 2017-03-31 2020-05-13 Altus Formulation Inc Non-ionic PVP-PLA block copolymers and pharmaceutical compositions derived therefrom
WO2021247463A1 (en) * 2020-06-02 2021-12-09 Purdue Research Foundation Formulation of monodisperse kinetically frozen polymer micelles via equilibration-nanoprecipitation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
CA2503361C (en) * 2002-10-25 2012-02-28 Labopharm Inc. Controlled-release compositions
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
US20070202158A1 (en) * 2003-12-17 2007-08-30 Mgi Gp, Inc. Methods Of Administering Water-Soluble Prodrugs Of Propofol For Extended Sedation
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2008035229A2 (en) * 2006-09-22 2008-03-27 Labopharm, Inc. Compositions and methods for ph targeted drug delivery
JP2010533730A (ja) * 2007-07-16 2010-10-28 ノースイースタン・ユニバーシティ 安定した治療用ナノ粒子
ES2731881T3 (es) * 2007-09-25 2019-11-19 Formulex Pharma Innovations Ltd Composiciones que comprenden compuestos activos lipófilos y método para su preparación
FR2930444B1 (fr) * 2008-04-29 2010-06-04 Servier Lab Micelles polymerisees
CA2797098C (en) * 2010-04-23 2019-03-26 Labopharm Inc. Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof

Also Published As

Publication number Publication date
WO2011130834A8 (en) 2013-01-10
JP2013530931A (ja) 2013-08-01
EP2563349A4 (en) 2014-03-19
IL222568A (en) 2017-05-29
IL222568A0 (en) 2012-12-31
JP6572256B2 (ja) 2019-09-04
WO2011130834A1 (en) 2011-10-27
JP2017186346A (ja) 2017-10-12
CA2797098A1 (en) 2011-10-27
EP2563349A1 (en) 2013-03-06
US20130039864A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
JP6572256B2 (ja) 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用
RU2523714C2 (ru) Полимерные системы доставки действующих веществ
CA2805525C (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
US20190224118A1 (en) Oral gastroretentive formulations and uses thereof
Wang et al. Recent advances in the nanotechnology-based drug delivery of Silybin
CN103585136A (zh) 用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物
KR20200130704A (ko) 약물 전달 시스템
US20210121414A1 (en) Method for producing a pharmaceutical composition of polymeric nanoparticles for treating neuropathic pain caused by peripheral nerve compression
Wang et al. A modified thin film method for large scale production of dimeric artesunate phospholipid liposomes and comparison with conventional approaches
NZ759175A (en) Particle and pharmaceutical composition comprising an insoluble camptothecin compound with double core-shell structure and method for manufacturing the same
US9504754B2 (en) Curcuminoid complexes with enhanced stability, solubility and/or bioavailability
Ramalho et al. Nanocarriers for the delivery of temozolomide in the treatment of glioblastoma: A review
Alinezhad et al. Utilization of curcumine and nanocurcumine compounds in cancer therapy
Maciejewska‐Stupska et al. Bioavailability enhancement of coenzyme Q10: An update of novel approaches
Richter et al. Polymeric micelles for parenteral delivery of sagopilone: physicochemical characterization, novel formulation approaches and their toxicity assessment in vitro as well as in vivo
Nagar et al. Synthesis, characterization and evaluation of retinoic acid-polyethylene glycol nanoassembly as efficient drug delivery system
WO2019094625A1 (en) Methods and compositions for parenteral administration of cannabidiol in the treatment of convulsive disorders
CN105012234B (zh) 一种二甲氧基姜黄素聚合物胶束及其制备方法与医药用途
CN106913882A (zh) 一种聚乙二醇‑藤黄酸脂质体和制备方法及其在治疗恶性肿瘤中的应用
Ibrahim Nanostructured lipid carriers for oral delivery of a corticosteroid: role of formulation on biopharmaceutical performance
Alavi et al. Green Formulation of Triglyceride/Phospholipid‐Based Nanocarriers as a Novel Vehicle for Oral Coenzyme Q10 Delivery
KR101329573B1 (ko) 인체유래 젤라틴 복합체 및 이의 용도
US20180064821A1 (en) Site specific curcumin-polymer molecular complexes and methods of treating colon diseases and inflammation
Chakraborty et al. Phospholipid-Based Nanoplatforms: Evolving as Promising Carriers for Therapeutic Intervention
Wu Formulation Development, Characterization, and Optimization of Antimalarial and Antibiotic Drugs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160405